Companies: 10,795·Total market cap: $144.5T
Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. Common Stock

BCAXNASDAQHealthcare● Active
$20.10
+$0.10(+0.50%)
Market Cap$1.1B
P/E Ratio
52W High$24.25
52W Low$8.48
Overview

Bicara Therapeutics Inc. Common Stock (BCAX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BCAX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.78bcax eps ttm · bcax earnings per shareEarnings history
PE Ratio (TTM)bcax pe ratio ttm · bcax price to earningsPE Ratio deep dive
Revenue (TTM)0.00bcax revenue ttm · bcax annual revenueFull revenue history
Dividend YieldNo Dividenddoes bcax pay dividends · bcax dividend yieldDividend history
Shares Outstanding54.7Mbcax shares outstanding · bcax floatShares outstanding history
Next EarningsAug 11, 2026Est.bcax earnings date · bcax next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
bicara therapeutics inc. common stock revenue · bcax revenue 2025
FY 2025Net Income-$137.9M▼ 102.88% YoY
202320242025
bicara therapeutics inc. common stock net income · bcax profit 2025
FY 2025EPS$-2.52▼ 101.60% YoY
202320242025
bcax eps · bicara therapeutics inc. common stock earnings per share 2025
TTM:Revenue: $0.00Net Income: -$157.3MEPS: $-2.78View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy7 analystsis bcax a buy · bcax analyst rating
Strong Buy
0
Buy
5
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$18.00Low
$20.10Current
$28.60Avg Target42.29% upside
$42.00High
bcax price target · bcax 12 month forecast

Total: 7 · Buy rate: 71.4%

The BCAX analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $28.60, representing +42.29% upside from the current price of $20.10.

Stock Performance

Full History
1D+0.50%
1W+2.39%
1M-10.98%
3M+8.83%
YTD+19.43%
1Y+75.09%
5Y-14.14%

About Bicara Therapeutics Inc. Common Stock

CEOClaire Mazumdar Clemon
IPO DateSep 13, 2024
Employees55
CountryUS
Websitebicara.com

Bicara Therapeutics Inc. Common Stock Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, du…

what is bicara therapeutics inc. common stock · bcax stock overview · bicara therapeutics inc. common stock company profile · who is bicara therapeutics inc. common stock ceo · bcax NASDAQ · bicara therapeutics inc. common stock headquarters · bicara therapeutics inc. common stock business segments

About Stock Overview & Key Data

Bicara Therapeutics Inc. Common Stock (BCAX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 13, 2024. As of the latest trading session, BCAX stock price is $20.10, with a market capitalization of $1.1B. The stock has returned +75.09% over the past 12 months and +19.43% year-to-date.

According to 7 Wall Street analysts, the consensus rating for Bicara Therapeutics Inc. Common Stock stock is Buy, with an average 12-month price target of $28.60. In fiscal year 2025, Bicara Therapeutics Inc. Common Stock reported revenue of — and net income of -$137.9M. For detailed data — including Bicara Therapeutics Inc. Common Stock revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Bicara Therapeutics Inc. Common Stock (BCAX) stock price is $20.10. The stock is traded on NASDAQ under the ticker symbol BCAX. The 52-week range is $8.48 – $24.25.

BCAX stock priceBCAX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice